PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
TRML vs. NVDL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between TRML and NVDL is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

TRML vs. NVDL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tourmaline Bio Inc. (TRML) and GraniteShares 2x Long NVDA Daily ETF (NVDL). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%100.00%AugustSeptemberOctoberNovemberDecember2025
24.00%
2.49%
TRML
NVDL

Key characteristics

Sharpe Ratio

TRML:

-0.51

NVDL:

2.75

Sortino Ratio

TRML:

-0.29

NVDL:

2.90

Omega Ratio

TRML:

0.96

NVDL:

1.36

Calmar Ratio

TRML:

-0.47

NVDL:

5.64

Martin Ratio

TRML:

-0.76

NVDL:

14.14

Ulcer Index

TRML:

52.78%

NVDL:

20.52%

Daily Std Dev

TRML:

79.23%

NVDL:

105.50%

Max Drawdown

TRML:

-94.97%

NVDL:

-51.40%

Current Drawdown

TRML:

-77.93%

NVDL:

-21.15%

Returns By Period

In the year-to-date period, TRML achieves a -10.06% return, which is significantly lower than NVDL's 1.25% return.


TRML

YTD

-10.06%

1M

-17.47%

6M

19.45%

1Y

-43.18%

5Y*

N/A

10Y*

N/A

NVDL

YTD

1.25%

1M

3.69%

6M

8.18%

1Y

273.27%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

TRML vs. NVDL — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TRML
The Risk-Adjusted Performance Rank of TRML is 2525
Overall Rank
The Sharpe Ratio Rank of TRML is 2121
Sharpe Ratio Rank
The Sortino Ratio Rank of TRML is 2626
Sortino Ratio Rank
The Omega Ratio Rank of TRML is 2626
Omega Ratio Rank
The Calmar Ratio Rank of TRML is 1919
Calmar Ratio Rank
The Martin Ratio Rank of TRML is 3232
Martin Ratio Rank

NVDL
The Risk-Adjusted Performance Rank of NVDL is 8989
Overall Rank
The Sharpe Ratio Rank of NVDL is 9696
Sharpe Ratio Rank
The Sortino Ratio Rank of NVDL is 8585
Sortino Ratio Rank
The Omega Ratio Rank of NVDL is 8080
Omega Ratio Rank
The Calmar Ratio Rank of NVDL is 9797
Calmar Ratio Rank
The Martin Ratio Rank of NVDL is 8888
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

TRML vs. NVDL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Tourmaline Bio Inc. (TRML) and GraniteShares 2x Long NVDA Daily ETF (NVDL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for TRML, currently valued at -0.51, compared to the broader market-2.000.002.00-0.512.75
The chart of Sortino ratio for TRML, currently valued at -0.29, compared to the broader market-4.00-2.000.002.004.00-0.292.90
The chart of Omega ratio for TRML, currently valued at 0.96, compared to the broader market0.501.001.502.000.961.36
The chart of Calmar ratio for TRML, currently valued at -0.55, compared to the broader market0.002.004.006.00-0.555.64
The chart of Martin ratio for TRML, currently valued at -0.76, compared to the broader market-30.00-20.00-10.000.0010.0020.00-0.7614.14
TRML
NVDL

The current TRML Sharpe Ratio is -0.51, which is lower than the NVDL Sharpe Ratio of 2.75. The chart below compares the historical Sharpe Ratios of TRML and NVDL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.006.00AugustSeptemberOctoberNovemberDecember2025
-0.51
2.75
TRML
NVDL

Dividends

TRML vs. NVDL - Dividend Comparison

Neither TRML nor NVDL has paid dividends to shareholders.


TTM20242023
TRML
Tourmaline Bio Inc.
0.00%0.00%57.75%
NVDL
GraniteShares 2x Long NVDA Daily ETF
0.00%0.00%11.29%

Drawdowns

TRML vs. NVDL - Drawdown Comparison

The maximum TRML drawdown since its inception was -94.97%, which is greater than NVDL's maximum drawdown of -51.40%. Use the drawdown chart below to compare losses from any high point for TRML and NVDL. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-60.04%
-21.15%
TRML
NVDL

Volatility

TRML vs. NVDL - Volatility Comparison

The current volatility for Tourmaline Bio Inc. (TRML) is 16.12%, while GraniteShares 2x Long NVDA Daily ETF (NVDL) has a volatility of 25.15%. This indicates that TRML experiences smaller price fluctuations and is considered to be less risky than NVDL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%AugustSeptemberOctoberNovemberDecember2025
16.12%
25.15%
TRML
NVDL
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab